Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

darexaban glucuronide

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
We investigated the effects of ketoconazole on the pharmacokinetics (PK) of the direct clotting factor Xa inhibitor darexaban… Expand
2013
2013
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
2013
2013
Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial… Expand
2013
2013
1. The absorption, metabolism and excretion of darexaban (YM150), a novel oral direct factor Xa inhibitor, were investigated… Expand
2013
2013
The oral direct factor Xa inhibitor darexaban administered intraduodenally prevented venous thrombus formation in both rats and… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
2013
2013
BACKGROUND Darexaban is a potent direct factor Xa (FXa) inhibitor developed for prophylaxis of venous and arterial thromboembolic… Expand
2013
2013
Here, we investigated the anticoagulant effects of darexaban in mice and human plasma in vitro, effects of darexaban in… Expand
2012
2012
Darexaban maleate is a novel oral direct factor Xa inhibitor. Darexaban glucuronide (YM-222714) was the major component in plasma… Expand
2012
2012
Most synthetic factor Xa (FXa) and thrombin inhibitors examined in pharmacokinetic studies and phase II/III clinical trials have… Expand
2011
2011
Darexaban (YM150) is an oral factor Xa inhibitor developed for the prophylaxis of venous and arterial thromboembolic disease… Expand